You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盛禾生物遞表港交所,估值14億,開發多種免疫療法
格隆匯 08-04 11:53

8月3日,Sunho Biologics,Inc.(下稱:盛禾生物)向港交所遞交了招股書,擬在香港主板掛牌上市,中金公司為其獨家保薦人。

圖片來源:招股書

值得一提的是,2023年5月31日,公司完成一輪2.1億元的融資,投後估值約14.1億元。其中,倚鋒安盛以代價1.4億元認購5,833.33股股份,倚鋒安禾以代價7000萬認購2,916.67股股份。

截至最後實際可行日期,張先生通過Sunho Fortune、Innovalue Investments、Sunho Wisdom、No5XJR以及Sunho Stellar可行使公司約85.11%的投票權。

盛禾生物成立於2021年,是一家生物製藥公司,致力於發現、開發和商業化同類首創/同類最佳的生物製劑,通過直接調節先天和適應性免疫系統來調節免疫微環境

根據弗若斯特沙利文的資料,公司是開發抗體細胞因子產品的全球領先公司之一,並且是少數擁有臨牀進展最快的抗體細胞因子候選產品的先行者之一。

目前公司已開發9個管線產品,其中6個處於臨牀階段(IAP0971、IAE0972及IAH0968被認定為核心產品)。

其中,公司就IAP0971及IAE0972獲得國家藥監局及美國食品藥品監督管理局(「FDA」)對晚期實體瘤患者進行I/II期臨牀試驗的IND批准,並於2023年7月完成I期臨牀試驗。

另一核心產品IAH0968是一種抗體依賴性細胞介導的細胞毒性(「ADCC」)增強抗體,靶向人表皮生長因子受體2(「HER2」),100%敲除巖藻糖,大大增強了其可結芯片段(「Fc」)與受體FcγRIIIa的結合親和力。

此外,公司還在開發其他六個候選產品,即臨牀階段產品IBB0979、IBC0966及IBD0333,臨牀前階段產品IAN0982、ISH0988及ISH0613。

(公司管線產品具體情況,圖片來源:招股書)

經營業績方面,2021年、2022年、2023年前三月,公司的其他收入分別為322.4萬元、1379.5萬元、602.7萬元,相對應的年/期內虧損及綜合開支總額分別為-7063.2萬元、-5198.8萬元、-1531.1萬元。

公司其他收入主要包括政府補助、銀行利息收入、合約生產服務銷售收入及搬遷獎勵。

(綜合損益及其他全面收益表,圖片來源:招股書)

本次衝刺IPO,公司擬將所籌得資金的65.4%用於“核心產品的研發”;21.4%用於“其他臨牀管線候選產品的研發”;3.2%用於“其他臨牀前管線候選產品的臨牀前及計劃臨牀試驗”;10%用於“一般公司及營運資金用途”。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account